Kerlone Related Published Studies
Well-designed clinical trials related to Kerlone (Betaxolol)
Prevention of perioperative atrial fibrillation with betablockers in coronary surgery: betaxolol versus metoprolol. [2009.07]
Efficacy of brinzolamide and levobetaxolol in pediatric glaucomas: a randomized clinical trial. [2008.06]
Penetration of betaxolol HCL ionic suspension 0.25% and betaxolol HCL solution 0.50% into the aqueous humor. [2007.05]
Compliance, clinical outcome, and quality of life of patients with stable angina pectoris receiving once-daily betaxolol versus twice daily metoprolol: a randomized controlled trial. [2007]
Betaxolol is equivalent to carvedilol in patients with heart failure NYHA II or III: result of a randomized multicenter trial (BETACAR Trial). [2006.11.10]
Effects of latanoprost and betaxolol on cardiovascular and respiratory status of newly diagnosed glaucoma patients. [2006]
Effect of betaxolol hydrochloride on heart rate variability indices during exercise stress testing in patients with hypertension. [2005.10]
Well-designed clinical trials possibly related to Kerlone (Betaxolol)
The ability of short-wavelength automated perimetry to predict conversion to glaucoma. [2010.01]
Disc hemorrhages and treatment in the early manifest glaucoma trial. [2008.11]
Predictors of long-term progression in the early manifest glaucoma trial. [2007.11]
Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. [2007.02]
Treatment and vision-related quality of life in the early manifest glaucoma trial. [2005.09]
Other research related to Kerlone (Betaxolol)
Extracorporeal life support in a case of fatal flecainide and betaxolol poisoning allowing successful cardiac allograft. [2010.10]
Betaxolol hydrochloride ophthalmic suspension 0.25% and timolol gel-forming solution 0.25% and 0.5% in pediatric glaucoma: a randomized clinical trial. [2009.08]
Comparative effects of amlodipine monotherapy and combination therapy with betaxolol on cardiac autonomic nervous activity and health-related quality of life in patients with poorly controlled hypertension. [2008.05]
[Genetic aspects of individual sensitivity to betaxolol in patients with arterial hypertension] [2008]
Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension. [2007.08]
Betaxolol, a selective beta(1)-adrenergic receptor antagonist, diminishes anxiety-like behavior during early withdrawal from chronic cocaine administration in rats. [2007.06.30]
Penetration of betaxolol HCL ionic suspension 0.25% and betaxolol HCL solution 0.50% into the aqueous humor. [2007.05]
[The smoothness index of betaxolol hydrochloride in patients with newly diagnosed hypertension] [2007.01]
Protective effects of betaxolol in eyes with kainic acid-induced neuronal death. [2006.01.19]
Beta1-adrenergic receptor polymorphisms and clinical efficacy of betaxolol hydrochloride in normal volunteers. [2005.12]
[Clinical investigation: the intraocular pressure-lowering efficacy and safety of brinzolamide combined with betaxolol] [2005.12]
Other possibly related research studies
A comparison of the trough-to-peak ratio of cardio-selective beta-blockers in patients with newly diagnosed hypertension. [2006.12]
[Early Manifest Glaucoma Trial update 2004] [2005.03]
Prevalence of methylphenidate use among Israeli children: 1998-2004. [2006]
[Fundamentals of modern treatment of myopia] [2005]
Study of effects of antiglaucoma eye drops on N-methyl-D-aspartate-induced retinal damage. [2005.11]
Invited review: Neuroprotective properties of certain beta-adrenoceptor antagonists used for the treatment of glaucoma. [2005.06]
Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. [2005.07]
[Neonatal outcome after exposure to beta adrenergic blockers late in pregnancy] [2005.05]
Beta1 adrenergic receptors in the bed nucleus of stria terminalis mediate differential responses to opiate withdrawal. [2007.03]
Changes in glaucoma treatment and achieved IOP after introduction of new glaucoma medication. [2006.10]
Predictors of Long-term Progression in the Early Manifest Glaucoma Trial. [2007.07.10]
Ocular carteolol: a review of its use in the management of glaucoma and ocular hypertension. [2007]
Sympathetic nervous modulation of the skin innate and adaptive immune response to peptidoglycan but not lipopolysaccharide: involvement of beta-adrenoceptors and relevance in inflammatory diseases. [2008.01]
Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with essential arterial hypertension. [2008.01]
Benefits of a beta-blocker for intractable hemolysis due to paraprosthetic leakage. [2007.10]
Effects of switching from topical beta-blockers to latanoprost on intraocular pressure in patients with normal-tension glaucoma. [2008.04]
Disc Hemorrhages and Treatment in the Early Manifest Glaucoma Trial. [2008.08.07]
A network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressure. [2009.08.27]
Retrospective cohort study of 163 pediatric glaucoma patients. [2009.06]
Meta-analysis of medical intervention for normal tension glaucoma. [2009.07]
The safety and efficacy of glaucoma medication in the pediatric population. [2009.01]
Evidence for beta1-adrenergic receptor involvement in amygdalar corticotropin-releasing factor gene expression: implications for cocaine withdrawal. [2009.04]
[Analysis of the effectiveness of beta-blockers for intraocular pressure and visual field in primary open-angle glaucoma] [2008]
[Neuroprotection in glaucoma] [2007]
Intraocular pressure reduction with a fixed treatment protocol in the Early Manifest Glaucoma Trial. [2010.03.17]
Influence of the extent of myopia on the progression of normal-tension glaucoma. [2010.05]
Post-retrieval disruption of a cocaine conditioned place preference by systemic and intrabasolateral amygdala beta2- and alpha1-adrenergic antagonists. [2009.11.25]
Topical beta blockers in asthmatic patients-is it safe? [2009.07]
Is the medication used to achieve the target intraocular pressure in glaucoma therapy of relevance?--an exemplary analysis on the basis of two beta-blockers. [2010.01]
A network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressure. [2009.12]
Surveillance of glaucoma medical therapy in a Glasgow teaching hospital: 26 years' experience. [2009.12]
Effects of argon laser trabeculoplasty in the Early Manifest Glaucoma Trial. [2011.11]
Safety and efficacy of monotherapy change to fixed combination (travoprost 0.004%/timolol 0.5%) in 6 months follow up period. [2010.12]
Persistence of glaucoma medical therapy in the Glasgow Glaucoma Database. [2011.07]
Observational study of patients switched to the fixed travoprost 0.004%/timolol 0.5% combination in Croatia. [2010.10]
Use of calcium channel blockers for glaucoma. [2011.01]
Assessment of aqueous humor dynamics in the mouse by a novel method of constant-flow infusion. [2011.02.03]
Involvement of noradrenergic neurotransmission in the stress- but not cocaine-induced reinstatement of extinguished cocaine-induced conditioned place preference in mice: role for beta-2 adrenergic receptors. [2010.10]
Intraocular pressure reduction with a fixed treatment protocol in the Early Manifest Glaucoma Trial. [2011.12]
|
